KR101058467B1 - 부신피질 자극 호르몬 유사체 및 관련 방법 - Google Patents

부신피질 자극 호르몬 유사체 및 관련 방법 Download PDF

Info

Publication number
KR101058467B1
KR101058467B1 KR1020077011532A KR20077011532A KR101058467B1 KR 101058467 B1 KR101058467 B1 KR 101058467B1 KR 1020077011532 A KR1020077011532 A KR 1020077011532A KR 20077011532 A KR20077011532 A KR 20077011532A KR 101058467 B1 KR101058467 B1 KR 101058467B1
Authority
KR
South Korea
Prior art keywords
acth
peptide
adrenal
analog
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077011532A
Other languages
English (en)
Korean (ko)
Other versions
KR20070112761A (ko
Inventor
마일즈 비. 브렌난
로버트 엠. 도레스
캐리 하스켈-루에바노
유테 에이치. 호크게슈웬더
제시카 아이. 코스타
Original Assignee
유니버시티 오브 덴버
오클라호마 메디컬 리써치 화운데이션
유니버시티 오브 플로리다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 덴버, 오클라호마 메디컬 리써치 화운데이션, 유니버시티 오브 플로리다 filed Critical 유니버시티 오브 덴버
Publication of KR20070112761A publication Critical patent/KR20070112761A/ko
Application granted granted Critical
Publication of KR101058467B1 publication Critical patent/KR101058467B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020077011532A 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법 Expired - Fee Related KR101058467B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62243604P 2004-10-27 2004-10-27
US60/622,436 2004-10-27
PCT/US2005/038789 WO2006052468A2 (en) 2004-10-27 2005-10-27 Adrenocorticotropic hormone analogs and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020107020069A Division KR101150242B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법

Publications (2)

Publication Number Publication Date
KR20070112761A KR20070112761A (ko) 2007-11-27
KR101058467B1 true KR101058467B1 (ko) 2011-08-24

Family

ID=36336951

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127002771A Expired - Fee Related KR101242543B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법
KR1020077011532A Expired - Fee Related KR101058467B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법
KR1020107020069A Expired - Fee Related KR101150242B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127002771A Expired - Fee Related KR101242543B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107020069A Expired - Fee Related KR101150242B1 (ko) 2004-10-27 2005-10-27 부신피질 자극 호르몬 유사체 및 관련 방법

Country Status (13)

Country Link
US (4) US7919577B2 (enExample)
EP (2) EP2446894A3 (enExample)
JP (2) JP2008518026A (enExample)
KR (3) KR101242543B1 (enExample)
CN (2) CN101189022B (enExample)
AU (2) AU2005305157B2 (enExample)
CA (1) CA2584221A1 (enExample)
IL (1) IL182818A0 (enExample)
MX (1) MX2007004676A (enExample)
NZ (1) NZ554559A (enExample)
RU (2) RU2407751C2 (enExample)
SG (1) SG156680A1 (enExample)
WO (1) WO2006052468A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods
WO2009039968A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
CN104277105B (zh) * 2013-07-12 2017-12-12 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN103724427B (zh) * 2013-11-29 2016-09-28 青岛康原药业有限公司 一种精制促皮质素的方法
EP3084432B1 (en) * 2013-12-19 2018-03-21 Universiteit Gent Quantification of glucocorticoids in fish scales, spines, fin rays or otoliths as biomarkers for chronic stress
WO2015127288A1 (en) 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CA2973819A1 (en) 2014-12-19 2016-06-23 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
CN104530219A (zh) * 2014-12-23 2015-04-22 青岛康原药业有限公司 一种精制促皮质素的方法
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
CA3012190A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
CN105669856A (zh) * 2016-02-13 2016-06-15 王大勇 一种基因重组长效人促肾上腺皮质激素及其制备方法
CN116375797A (zh) * 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
CN106478771A (zh) * 2016-10-09 2017-03-08 李世军 一种氨基酸神经四肽的合成方法
US20180169191A1 (en) * 2016-12-19 2018-06-21 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
CN110698557B (zh) * 2019-11-06 2021-06-18 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒
US12433936B2 (en) 2021-04-12 2025-10-07 Nanjing Hanxin Pharmaceutical Technology Co., Ltd. High-purity adrenocorticotropic hormone analogue and a large-scale preparation method thereof
WO2022217395A1 (zh) * 2021-04-12 2022-10-20 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
CN120420414A (zh) * 2024-02-04 2025-08-05 南京汉欣医药科技有限公司 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US4415546A (en) 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5189018A (en) 1991-08-19 1993-02-23 Wayne State University Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
EP0831787B1 (en) 1995-06-07 2001-08-22 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
CN1305490A (zh) 1998-06-26 2001-07-25 辉瑞产品公司 改良的用于制备胺与邻羟基醛的席夫碱加合物的方法以及基于该物质的组合物
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001080830A2 (en) 2000-04-21 2001-11-01 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
TWI228512B (en) 2000-10-25 2005-03-01 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BRPI0413360A (pt) 2003-08-04 2006-10-10 Alza Corp método e dispositivo para aumentar o fluxo de agentes transdérmicos
EP1689457A2 (en) 2003-11-10 2006-08-16 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Endo. Rev. 14(4): 443-458 (1993)
Endocrine Journal 51(1): 89-95 (2004.2)
Gen. Comp. Endocrinol. 136(1): 12-16 (2004.3)

Also Published As

Publication number Publication date
NZ554559A (en) 2010-05-28
JP2012067099A (ja) 2012-04-05
AU2011201914A1 (en) 2011-05-19
US7919577B2 (en) 2011-04-05
US20100260681A1 (en) 2010-10-14
RU2007119580A (ru) 2008-12-10
WO2006052468A2 (en) 2006-05-18
EP2446894A2 (en) 2012-05-02
US20060128620A1 (en) 2006-06-15
AU2005305157A1 (en) 2006-05-18
KR101242543B1 (ko) 2013-03-22
US20080207518A1 (en) 2008-08-28
EP2446894A3 (en) 2013-02-20
CA2584221A1 (en) 2006-05-18
JP2008518026A (ja) 2008-05-29
CN101947310A (zh) 2011-01-19
KR20100102752A (ko) 2010-09-24
SG156680A1 (en) 2009-11-26
CN101189022B (zh) 2012-02-29
EP1814574A2 (en) 2007-08-08
MX2007004676A (es) 2007-11-14
US20070197774A1 (en) 2007-08-23
IL182818A0 (en) 2007-08-19
AU2005305157B2 (en) 2011-09-01
KR101150242B1 (ko) 2012-06-13
RU2010135499A (ru) 2012-02-27
KR20070112761A (ko) 2007-11-27
WO2006052468A3 (en) 2007-01-11
EP1814574A4 (en) 2009-08-05
KR20120050440A (ko) 2012-05-18
US7264314B2 (en) 2007-09-04
RU2407751C2 (ru) 2010-12-27
CN101189022A (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
KR101058467B1 (ko) 부신피질 자극 호르몬 유사체 및 관련 방법
JP2961708B2 (ja) 成長ホルモンとインスリン様成長因子―１の組み合わせが成長を増進する
JP2828250B2 (ja) 真性糖尿病の治療
JP4568383B2 (ja) 血管形成の促進方法
JPH05506030A (ja) 哺乳動物に組織修復促進の傾向を与える方法
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
KR19990014835A (ko) 근육 영양 인자
Leung et al. Mechanism (s) by which adrenalectomy and corticosterone influence prolactin release in the rat
JP2000510112A (ja) ＴＧＦ―β拮抗物質としてのプロラクチンの使用方法
HK1148194A (en) Adrenocorticotropic hormone analogs and related methods
CN120189521B (zh) 一种长链修饰的ghrh激动剂及其应用
KR20010024805A (ko) 베타-리포트로핀 및 그의 용도
Raja et al. Influence of TNF Alpha on Testosterone Induced Cardiac Effects in Isolated Frog Heart Model

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140817

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140817

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000